Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -21.3% | 21.1% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | 14.1 | 14.1 |
PEG | 2.2 | n/a |
Pr/Revenue | 1.9 | 1.8 |
Pr/Book | 1.6 |
Latest | F'cast | |
---|---|---|
Revenue | 7.9% | 4.2% |
PBT | n/a | n/a |
EPS | 6.3% | -4.4% |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-19 | 135.64 | 31.08 | 5.09p | 16.5 | 1.4 | +12% | 0.54p | 0.6% |
31-Dec-20 | 129.80 | 13.02 | 5.11p | 17.1 | n/a | 0% | 1.61p | 1.8% |
31-Dec-21 | 163.21 | 18.16 | 6.39p | 17.0 | 0.7 | +25% | 1.69p | 1.6% |
31-Dec-22 | 167.42 | (23.05) | 4.28p | 12.4 | n/a | -33% | 1.78p | 3.4% |
31-Dec-23 | 180.68 | (48.80) | 4.55p | 8.9 | 1.5 | +6% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-24 | 188.34 | 39.67 | 4.35p | 14.7 | n/a | -4% | n/a | 0.0% |
31-Dec-25 | 200.75 | 41.16 | 4.99p | 12.9 | 0.9 | +15% | n/a | 0.0% |
31-Dec-26 | 210.82 | 44.50 | 5.59p | 11.5 | 1.0 | +12% | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
Form 8.3 - APH LN | 28-Mar-2025 | 15:30 | RNS |
Form 8.3 ALLIANCE PHARMA PLC | 28-Mar-2025 | 15:03 | RNS |
Form 8.3 - [Alliance Pharma Plc] | 28-Mar-2025 | 15:01 | RNS |
Drug sales lead the way for Boots as revenues ri... | 31-Oct-2008 | The Scotsman |
Look ahead | 13-Sep-2006 | Times |
Look ahead | 12-May-2006 | Times |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 64.10p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 64.50 |
52 Week Low | 29.35 |
Volume | 2,588,915 |
Shares Issued | 540.57m |
Market Cap | £346.50m |
Beta | 0.00 |
RiskGrade | 119 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 0 |
Neutral | 5 |
Sell | 1 |
Strong Sell | 0 |
Total | 8 |
Latest | Previous | |
---|---|---|
Final | Interim | |
Ex-Div | 22-Jun-23 | 22-Dec-22 |
Paid | 18-Jul-23 | 19-Jan-23 |
Amount | 1.18p | 0.59p |
Time | Volume / Share Price |
16:35 | 49,522 @ 64.10p |
16:35 | 50 @ 64.10p |
16:35 | 99 @ 64.10p |
16:35 | 1 @ 64.10p |
16:35 | 1 @ 64.10p |
CFO | Andrew Franklin |
Chair | Camillo Pane |
CEO | Nick Sedgwick |
You are here: research